Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FT 516

Drug Profile

FT 516

Alternative Names: FT516; FT516i; hnCD16 engineered iPSC-derived NK cell therapy

Latest Information Update: 10 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Minnesota
  • Developer Fate Therapeutics; Masonic Cancer Center; University of Minnesota
  • Class Antineoplastics; Gene therapies; Immunotherapies; Induced pluripotent stem cell therapies; Natural killer cell therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; B-cell lymphoma; COVID 2019 infections; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours

Most Recent Events

  • 23 Oct 2023 Fate Therapeutics terminates a phase I trial in Acute myeloid leukaemia (Second-line therapy or greater) and B-cell lymphoma (Second-line therapy or greater, Combination therapy) in USA (Parenteral) (NCT04023071)
  • 21 Sep 2023 Fate Therapeutics terminates a phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral) due to the sponsor decison (NCT04551885)
  • 05 Jan 2023 Discontinued - Phase-I for Acute myeloid leukaemia (Second-line therapy or greater) in USA (Parenteral)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top